Related Experiment Video
Updated: Nov 26, 2025
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
517
Minimum clinical important difference for resilience scale specific to cancer: a prospective analysis
Zeng Jie Ye1, Zhang Zhang2, Ying Tang3
1Guangzhou University of Chinese Medicine, Guangzhou, 510006, Guangdong Province, China. zengjieye@qq.com.
Health and Quality of Life Outcomes
|December 10, 2020
Summary
The minimum clinical important differences (MCIDs) for cancer resilience scales were evaluated. Reliable MCIDs are approximately 5 points for the 25-item scale and 2 points for the 10-item scale, aiding future cancer resilience research.
Area of Science:
- Oncology
- Psychometrics
- Health Outcomes Research
Background:
- Minimum Clinical Important Differences (MCIDs) for cancer-specific resilience instruments are not well-established.
- This study aimed to determine MCIDs for the 10-item (RS-SC-10) and 25-item (RS-SC-25) Resilience Scales specific to Cancer.
Purpose of the Study:
- To evaluate the MCIDs of the RS-SC-10 and RS-SC-25 in patients with cancer.
- To provide reliable estimates for interpreting changes in resilience scores in cancer populations.
Main Methods:
- Longitudinal measurement of RS-SC-10 and RS-SC-25 in 765 cancer patients over 3 months.
- Concurrent measurement of anchor instruments including EORTC QLQ-C30 and Hospital Anxiety and Depression Scale.
- Application of anchor-based (linear regression, within-group), distribution-based (within-group), and receiver operating characteristic (ROC) curve analyses.
Main Results:
- Moderate correlations (r=0.38-0.44) were found between changes in RS-SC scores and anchor changes.
- MCID estimates for RS-SC-25 ranged from +/- 5.5 to +/- 9.9, and for RS-SC-10 from +/- 1.5 to +/- 4.0 across methods.
- Linear regression yielded MCIDs of +/- 8.9 and +/- 3.4 for RS-SC-25 and RS-SC-10, respectively.
Conclusions:
- The most reliable MCID estimates are approximately 5 points for RS-SC-25 and 2 points for RS-SC-10.
- Resilience Scales specific to Cancer (RS-SCs) demonstrate responsiveness to worsening resilience in cancer patients.
- These MCID estimates are valuable for future resilience-focused intervention trials in oncology.
Related Concept Videos
01:21Cancer Survival Analysis
533
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
533
01:20Comparing the Survival Analysis of Two or More Groups
415
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
415
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
272
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
272
01:12Relative Risk
1.3K
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
1.3K
01:52Regression Toward the Mean
6.6K
Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
6.6K
02:56Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K